secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncotelic Therapeutics, Inc. (OTLC)
CIK:        0000908259
Form:       8-K
Filed at:   2025-03-25T23:59:59+00:00
Accession:  0001641172-25-000537
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncotelic announces successful Phase 1 of OT-101/IL-2 for solid tumors; plans combo studies with checkpoint inhibitors
--------------------------------------------------------------------------------

- Phase 1 trial (NCT04862767) of OT-101 + IL-2 in advanced solid tumors shows tolerable safety, no unexpected signals.
- Based on safety data, Oncotelic plans to advance OT-101 + IL-2 into studies with checkpoint inhibitors (e.g., PD-1 blockers) for lung, melanoma, colorectal cancers.
- OT-101 is also in Phase 3 STOP-PC study for pancreatic cancer and has shown activity in gliomas.
- CEO Dr. Vuong Trieu presented on TGFβ2's role in immune suppression at SWCR 2025 conference.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/908259/000164117225000537/0001641172-25-000537-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/908259/000164117225000537/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-000537

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer